Road to Clinical Validation of NBE-002, a Novel PNU-anthracycline-based ROR1 Targeting iADC in Solid Tumours

Time: 9:20 am
day: Day Two


  • Understand rationales for targeting ROR1 in solid tumour patients
  • Analyse preliminary data from a phase I/IIa clinical study with NBE-002, a novel ROR1-targeting iADC
  • Gain an overview of clinical study design and biomarker strategy for future efficacy studies, based on NBE-002’s mode of action